Direct, Definitive Single-Cell Genomics
Biomarker Discovery, Genomic Modification and DNA Delivery
Through expert scientific support and unparalleled genomics tools and services, KromaTiD is helping research teams in academia, pharma and biopharma accelerate delivery of novel therapeutics to the patients who need them. Let us be your partner for biomarker discovery, genotoxicity studies, genome-editing screens and plasmid manufacturing.
.
Single-Cell Genomic Assays: Products and Services
From plasmid manufacturing to single-cell assessment of genome edits, KromaTiD products and services help researchers in academia and biopharma develop novel therapeutics. Our patented directional Genomic Hybridization™ (dGH™) technology provides superior, unbiased assay results for identification of CRISPR/Cas on/off targets, genomic structural variants and stability. KromaTiD can provide end-to-end service or you can use the dGH Assay Cell Prep Kit to prepare cell samples in your own lab.
FISH Probes and Services
KromaTiD’s next-level fluorescence in situ hybridization probes and services provide robust, easily enumerable fluorescent signals with high signal-to-noise ratios, enabling you to optimize your traditional FISH assays. Our tools allow researchers to expand beyond the capabilities of conventional FISH probes to detect smaller targets and design ultra-high specificity tests.
Research Services
We provide research services for pharmaceutical and biotechnology companies in life sciences. Our expertise in cell culture and G-banding analysis gives you back precious time and resources to focus on other critical research questions.
KromaTiD News
Company News | Press
- Longmont Leader Article on KromaTiD’s Plasmid Manufacturing Service
- KromaTiD Announces Launch of Plasmid Manufacturing Services
- KromaTiD Announces Launch of dGH Cell Prep Kit
- KromaTiD Announces Launch of Pinpoint FISH™ DNA Probes
- Just Up on the Blog! KromaTiD’s Dark Lab Files: The Great Race to Cure Cancer – CAR-T Segment
- Register for KromaTiD’s directional Genomic Hybridization™ Webinar Featured on GEN News April 27th
- Just Up on the Blog! KromaTiD’s Dark Lab Files: Cytogenetics a Little History Lesson
- KromaTiD Announces Launch of Cell Culture Services
- KromaTiD Announces EARLY ACCESS Launch of TP53/CEP17 Kit for Synthetic Oligonucleotide-Based FISH Assay
- KromaTiD Announces Launch of dGH SCREEN™
- Applied Spectral Imaging and KromaTiD announce strategic commercial partnership
- KromaTiD and dGH in-Site featured in Genetic Engineering & Biotechnology News
Videos | Presentations | Webinars
- KromaTiD Webinar dGH SCREEN October 4, 2022
- KromaTiD Webinar CRISPR Off Target Gene Editing (GEN News)
- KromaTiD Presents at Next Gen Omics Boston
- KromaTiD’s Cell Culture Services Protocol
- Gene Therapy Online – Europe
- Life Science Tuesday – Austria
- Dr. Chris Tompkins and Erin Cross present webinar for the launch of dGH SCREEN™ for unbiased whole genome analysis of chromosomal structural rearrangements
- Dr. Lauren Kinner-Bibeau presents webinar on single-cell measurements of genomic inserts and transgenes
- KromaTiD presents at the 2020 virtual NextGen Omics Series
- KromaTiD CTO Dr. Chris Tompkins presents at the 2020 Cell & Gene Therapy Virtual Congress
Market News
- JPM:23 With pre-clinical gene writing on display, Tessera CEO’s spirit not dampened by California’s Wild Weather
- A trio of Biotechs Consolidate as M&A Fails to Materialize at JP Morgan
- Vertex Expands Gene-Editing Partnership with Arbor
- FDA Fast Track Caribou Biosciences Allogenic Anti CD19 CAR-T
- AstraZeneca Deepens Cancer Cell Therapy Portfolio with Neogene Buyout
- Harmonizing the Community of Genome Editing with the First Set of Standardized Terms (NIST)
- GSK’s CAR-T rival Blenrep fails multiple myeloma trial, endangering its accelerated approval
- Novartis’ $3B Prospect beats AstraZeneca Blockbuster in Phase 3
- Prime Medicine Raises $175M in one of the year’s largest Biotech IPO’s
- Bluebird on a Roll with Second FDA Approval in Matter of Weeks
- Intellia’s Latest Data Indicates Full Potential of CRISPR
- Guardant, Merck KGaA expand precision therapeutics collab, focusing on hard-to-treat cancer
- J&J bags first nod for multiple myeloma bispecific to complement its own CAR-T offering